🔥 The pharmaceutical giant may be gearing up for a stock market comeback!

Pfizer ($PFE.US ) is back on investors’ radar! With quarterly results released, financial guidance revised upward, and growth in new medications, the company is showing signs worth watching.

But has the time come for investors to bet on PFE’s recovery?

📊 NUMBERS THAT CATCH THE EYE!

💰 Reference price: US$ 30.83

🔺 High: US$ 31.11

🔻 Low: US$ 30.67

📈 Change: +0.49%

🌎 Pre-market: US$ 30.512 (-0.51%)

📉 EMA 9: US$ 30.50

📉 EMA 21: US$ 30.58

📊 RSI: 50.80

An RSI close to 50 indicates a balance between buyers and sellers. The battle around US$ 31 could be important in determining the next move.

💥 RESULTS THAT COULD CHANGE THE GAME!

Pfizer reported notable third-quarter figures:

  • Revenue: US$ 16.58 billion.

  • Adjusted earnings per share: US$ 0.87.

  • Net income: US$ 3.24 billion.

  • 32% growth in launched and acquired products.

  • New full-year revenue forecast: US$ 62 to US$ 64 billion.

🚀 Another highlight: the company raised its 2026 adjusted earnings-per-share forecast to US$ 2.95–3.05.

This could represent a recovery opportunity, but the market still needs to assess whether this growth is sustainable.

🎯 CAN PFE BREAK ABOVE US$ 31?

Watch these key levels:

🟢 Resistance: US$ 31.11. A breakout on strong volume could strengthen buyers.

🔴 Support: US$ 30.67. A drop below this area could increase selling pressure.

📊 Moving averages: EMA 9 at US$ 30.50 and EMA 21 at US$ 30.58.

The situation deserves attention: operational growth, dividends, and new projections could support the stock, but competition, patents, and declining COVID-19-related revenue remain challenges.

💰 AND WHAT ABOUT THE DIVIDENDS? DOES PFE DESERVE A PLACE IN YOUR PORTFOLIO?

Pfizer continues to attract the attention of investors interested in passive income. However, dividends are no guarantee of returns, and the share price can also fall.

🔥 MY QUESTION FOR YOU:

If you had US$ 100 available today, would you buy Pfizer shares for the dividends and potential recovery, or choose another company in the pharmaceutical sector?

👇 I’d love to hear about your strategy in the comments!

👍 Leave a like to support this analysis.

🔄 Share this with other investors.

🎁 If you found this content useful, consider sending a TIP to support the creation of more financial analyses and news!

#PFE #Pfizer #Dividends #USStocks #Investing #StockMarket #FinancialMarkets #BinanceSquare